Literature DB >> 28984058

Multivariate analysis of risk factors for cisplatin-induced nephrotoxicity in gynecological cancer.

Yoshihiro Yamamoto1, Kazushi Watanabe2, Hiroshi Matsushita2, Ikuto Tsukiyama1, Katsuhiko Matsuura1, Akihiko Wakatsuki2.   

Abstract

AIM: Risk factors for cisplatin-induced nephrotoxicity (CIN) vary by population. This study aimed to assess risk factors for CIN in patients with gynecological cancer.
METHODS: Patients who underwent cisplatin-based chemotherapy for gynecological cancer between January 2009 and December 2015 at Aichi Medical University School of Medicine were included in this study. CIN was defined according to the 'risk, injury, failure, loss, and end-stage kidney disease' (RIFLE) criteria and classified as either risk (Class R) or injury (Class I). Analyses were performed using univariate and multivariate logistic regression models.
RESULTS: Among 112 patients enrolled, 30 had CIN. Multivariate analysis revealed that hydration with magnesium (odds ratio [OR], 0.223), history of cisplatin use (OR, 4.420), and hypoalbuminemia (OR, 4.170) were risk factors for Class R, and that frequency of cisplatin administration (OR, 5.620) and hydration with magnesium (OR, 0.216) were risk factors for Class I.
CONCLUSION: This study confirmed that hydration without magnesium, history of cisplatin use, frequency of cisplatin administration, and hypoalbuminemia are significant risk factors for CIN.
© 2017 Japan Society of Obstetrics and Gynecology.

Entities:  

Keywords:  cisplatin; gynecological cancer; hypoalbuminemia; magnesium; nephrotoxicity

Mesh:

Substances:

Year:  2017        PMID: 28984058     DOI: 10.1111/jog.13457

Source DB:  PubMed          Journal:  J Obstet Gynaecol Res        ISSN: 1341-8076            Impact factor:   1.730


  6 in total

1.  Prevention of Cisplatin-Induced Acute Kidney Injury: A Systematic Review and Meta-Analysis.

Authors:  Aghilès Hamroun; Rémi Lenain; Jean Joel Bigna; Elodie Speyer; Linh Bui; Paul Chamley; Nicolas Pottier; Christelle Cauffiez; Edmone Dewaeles; Xavier Dhalluin; Arnaud Scherpereel; Marc Hazzan; Mehdi Maanaoui; François Glowacki
Journal:  Drugs       Date:  2019-09       Impact factor: 9.546

2.  Comparison of Equations To Estimate Glomerular Filtration Rate and Their Impact on Frequency of Cisplatin-associated Acute Kidney Injury.

Authors:  Shveta S Motwani; Toni K Choueiri; Ann H Partridge; Jiani Hu; Marina D Kaymakcalan; Sushrut S Waikar; Gary C Curhan
Journal:  Kidney360       Date:  2020-12-29

3.  Comparison of Myelotoxicity and Nephrotoxicity Between Daily Low-Dose Cisplatin With Concurrent Radiation and Cyclic High-Dose Cisplatin in Non-Small Cell Lung Cancer Patients.

Authors:  Zulfan Zazuli; Renate Kos; Joris D Veltman; Wilma Uyterlinde; Cristina Longo; Paul Baas; Rosalinde Masereeuw; Susanne J H Vijverberg; Anke-Hilse Maitland-van der Zee
Journal:  Front Pharmacol       Date:  2020-06-26       Impact factor: 5.810

Review 4.  Cisplatin-induced renal toxicity in elderly people.

Authors:  ZhiYu Duan; GuangYan Cai; JiJun Li; XiangMei Chen
Journal:  Ther Adv Med Oncol       Date:  2020-05-18       Impact factor: 8.168

5.  Insonation of Systemically Delivered Cisplatin-Loaded Microbubbles Significantly Attenuates Nephrotoxicity of Chemotherapy in Experimental Models of Head and Neck Cancer.

Authors:  Hang-Kang Chen; Shu-Mei Zhang; Junn-Liang Chang; Hsin-Chien Chen; Yi-Chun Lin; Cheng-Ping Shih; Huey-Kang Sytwu; Mei-Cho Fang; Yuan-Yung Lin; Chao-Yin Kuo; Ai-Ho Liao; Yueng-Hsiang Chu; Chih-Hung Wang
Journal:  Cancers (Basel)       Date:  2018-09-05       Impact factor: 6.639

6.  Renal function impairment in cervical cancer patients treated with cisplatin-based chemoradiation: A review of medical records in a Zimbabwean outpatient department.

Authors:  Pinky M C Manyau; Mensil Mabeka; Tinashe Mudzviti; Webster Kadzatsa; Albert Nyamhunga
Journal:  PLoS One       Date:  2021-02-24       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.